Abstract Details
|
PRESENTER |
No disclosure on file |
| William E. Rosenfeld, MD, FAAN (Comprehensive Epilepsy Care Center for Children and Adults) | The institution of Dr. Rosenfeld has received personal compensation in the range of $500,000-$999,999 for serving as a Consultant for SK Life Science. Dr. Rosenfeld has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for SK Life Science. |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| Pablo Villoslada, MD, PhD, FAAN (Hospital del Mar Research Institute) | Dr. Villoslada has received personal compensation for serving as an employee of Attune Neuroscience. Dr. Villoslada has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Accure Therapeutics. Dr. Villoslada has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Oculis. Dr. Villoslada has stock in Attune Neurosciences. Dr. Villoslada has stock in Bionure Investments. Dr. Villoslada has stock in Spiral Therapeutics. Dr. Villoslada has stock in Adhera Health. The institution of Dr. Villoslada has received research support from Start2Cure Foundation. The institution of Dr. Villoslada has received research support from NIH. The institution of Dr. Villoslada has received research support from Department of Defense. Dr. Villoslada has received intellectual property interests from a discovery or technology relating to health care. |